Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study

AIDS

Volumn 23, Issue 12, 2009, Pages 1539-1546

  McKinnell, James A ^a   Lin, Hui Yi ^b   Nevin, Christa N ^a   Willig, James H ^a   McFarland, Graeme ^a   Genz, Michael ^a   Raper, James L ^a   Delaitsch, Lori L ^c   Mrus, Joseph M ^c   Klaskala, Winslow ^c   Mugavero, Michael J ^a   Saag, Michael S ^a,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Tibotec Therapeutics   (United States)

^d NONE   (United States)

Author keywords

Antiretroviral therapy; Darunavir; HIV AIDS; Protease inhibitors; Raltegravir; Resistance

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PYRROLIDINONES; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 68649127622     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832c7b5c     Document Type: Article

References (20)

1. Clotet B, Beilos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
2. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
3. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
4. Haubrich R, Cahn P, Griinstein B, Lalezari J, Madruga J, Mills A, et al. DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC 125 vs placebo in 591 treatment-experienced HIV-1 infected patients. In: 15th Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts, USA; 2008.
5. Johnson M, Campbell T, Clotet B, Katlama C, Lazzarin A, Towner W, et al. DUET-2: 48-week results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 infected patients. In: 15th Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts, USA; 2008.
6. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment- experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.
7. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18.
8. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
9. Adolescents. PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2008. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf.
10. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006; 42:1003-1010.
11. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998; 17:2265-2281.
13. Deeks S, (NA-ACCORD) NAACCoRaD. Trends in second virologie failure and predictors of subsequent mortality among ART-experienced patients: North American experience. In: 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February 2008; Boston, Massachusetts, USA; 2008.
14. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007; 370:29-38.
15. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007; 370:39-48.
16. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
17. Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, et al. Prevalence and risk factors for etravirine resistance among patients failing on nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2008; 13:601-605.
18. Llibre JM, Santos JR, Puig T, Molto J, Ruiz L, Pa redes R, Clotet B. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62:909-913.
19. Boyd MA, Truman M, Hales G, Anderson J, Dwyer DE, Carr A. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antivir Ther 2008; 13:449-453.
20. Edmunds-Ogbuokiri T. An in-depth look at the challenges of prescribing maraviroc. HIV Clin 2008; 20:9-11.